US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
16-Jun-16
$40 million

Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.